TOday’s Movers: Aerpio Pharmaceuticals Inc (ARPO) Stock Rating Maintained at H.C. Wainwright; $10.0000 Target Price Indicates 147.52 % Potential

May 16, 2018 - By Vivian Currie

Aerpio Pharmaceuticals Inc (ARPO) Rating Reaffirmed

They currently have a $10.0000 target on Aerpio Pharmaceuticals Inc (ARPO). The target price by H.C. Wainwright would suggest a potential upside of 147.52 % from the company’s close price. This has been revealed to clients and investors in a report on Wednesday morning.

The stock decreased 0.25% or $0.01 during the last trading session, reaching $4.04. About 14,807 shares traded or 60.58% up from the average. Aerpio Pharmaceuticals, Inc. (ARPO) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company has market cap of $109.65 million. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It currently has negative earnings. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: